Next Article in Journal
Quality by Design Approach Using Multiple Linear and Logistic Regression Modeling Enables Microemulsion Scale Up
Previous Article in Journal
Aptitude of Oxidative Enzymes for Treatment of Wastewater Pollutants: A Laccase Perspective
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 11
10.3390/molecules24112065
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, Antimicrobial, and Anticancer Activities of Acridine Thiosemicarbazides Derivatives

by
Rui Chen
1,2,
Lini Huo
1,*,
Yogini Jaiswal
3,
Jiayong Huang
1,
Zhenguo Zhong
1,
Jing Zhong
1,
Leonard Williams
3,
Xing Xia
1,
Yan Liang
4 and
Zhenshuo Yan
1
1
College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530222, China
2
Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning 530222, China
3
Center for Excellence in Post-Harvest Technologies, North Carolina A&T State University, The North Carolina Research Campus, 500 Laureate Way, Kannapolis, NC-28081, USA
4
College of Pharmacy, Guangxi Medical University, Nanning 530021, China
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(11), 2065; https://doi.org/10.3390/molecules24112065
Submission received: 3 May 2019 / Revised: 23 May 2019 / Accepted: 24 May 2019 / Published: 30 May 2019
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
Background: Acridine and thiourea derivatives are important compounds in medicinal chemistry due to their diverse biological properties including anticancer and antimicrobial effects. However, literature reveals some side effects associated with use of acridines. It is suggested that hybrid molecules may reduce the side effects and enhance the beneficial properties due to synergistic activity. The objectives of the present study are to synthesize and evaluate the anticancer and antimicrobial properties of new hybrids of acridine thiosemicarbazides derivatives. Results: The structures of the synthesized compounds 4a–4e were elucidated by MS and NMR spectra. In antimicrobial assay, Compound 4c exhibited potent antimicrobial activity compared to the other four compounds. In anticancer studies, we observed that compounds 4a, 4b, 4d and 4e exhibited high cytotoxicity against the MT-4 cell line, with IC50 values of 18.42 ± 1.18, 15.73 ± 0.90, 10.96 ± 0.62 and 11.63 ± 0.11 μM, respectively. The evaluation of anticancer effects, and the associated mechanism reveals that, the anticancer activities may be related to Topo I inhibitory activity, apoptosis and cell-cycle. Molecular docking studies revealed that the presence of planar naphtho-fused rings and a flexible thiourea group together, could improve DNA-intercalation and inhibition of DNA-Topo I activity. Conclusions: The results of this study demonstrate that the rational design of target derivatives as novel antimicrobial or antitumor leads is feasible.

1. Introduction

Natural and synthetic acridine derivatives are a series of heterocyclic compounds that are of considerable interest for medicinal chemists and are widely used as anti-inflammatory, antibacterial and antitumor agents [1]. Acridine is a potential compound for developing new anticancer drugs due to its planar structure that can strongly bind to DNA [2]. The cytotoxicity effect of most clinically useful DNA-intercalating agents involves the inhibition of the enzyme DNA-topoisomerase I or II [3]. Acridine compounds are able to inhibit topoisomerase I and II enzymes, render a DNA damage, disrupt DNA repair and replication, and induce cell death [4,5,6]. Amsacrine (m-AMSA, 1) and N-[(2-dimethylamino)ethyl] acridine-4-carboxamide (DACA, 2) are the most common acridine DNA-topoisomerase inhibitors. For example, m-AMSA and its analogue (3) have been clinically used for treatment of leukemia due to their DNA-intercalation activity and inhibition of the enzyme DNA-topoisomerase I or II [7,8,9]. DACA is a new DNA-intercalating agent with inhibitory activity against the enzymes topoisomerase I and topoisomerase II. It is currently in clinical trial as an anticancer drug for patients with non-small cell lung cancer and advanced ovarian cancer [10]. Compounds or derivatives with above-mentioned acridine structure, are antitumor cytotoxic agents with DNA-intercalative properties. Their specific characteristics include; (1) the presence of the planar acridine-platform and, (2) one or two flexible substituent groups. Molecules 24 02065 i001
Thiourea and sulfonamide derivatives have gained attention of medicinal chemists due to their wide range of biological activities, which include; antitumor, antiviral, antimicrobial, antiparasitic, and fungicidal effects [11,12,13,14,15,16]. Unfortunately, the use of some acridines has been limited due to issues such as side effects, drug resistance and poor bioavailability [3]. There is a rising need for development of new acridine compounds and derivatives possessing potent antitumor activities, but with reduced side effects. A new approach to reduce drug resistance, is the synthesis of hybrid molecules with enhanced activities [17]. Hybridization of two bioactive molecules often leads to increased activity due to synergistic effects. A strong prevalence of intramolecular hydrogen bonding between the thiourea group and the receptor pocket helps in improving the bioactivities of compounds [18].
In light of the above-mentioned considerations for anticancer agents with enhanced activity and reduced side effects, the objective of this study was to synthesize potential anti-cancer compounds that are hybrids of acridine and thiourea group (Figure 1). A new naphtho-fused ring was added in the acridine structure for increasing the DNA imbedding by their planar platform. The objectives of the study also include an investigation of the mechanism of action of these compounds for topo I inhibition, cell apoptosis and selectivity for the cellular cycle. As acridine derivatives are reported to exhibit other pharmacological properties such as antibacterial effects, the synthesized compounds were screened for antibacterial activity.

2. Results and Discussion

2.1. Chemistry

The general synthetic approach for acridinyl acylthiourea derivatives (4) is illustrated in Scheme 1. Naphtho-fused acridinyl skeleton (2) was obtained from the classic synthetic methods of acridine. Isothiocyanate 3 was obtained from Compound 2 with nucleophilic substitution. The target compounds 4a–4e were synthesized by the condensation of aryl hydrazides with naphtho-fused acridinyl isothiocyanates (3), and their yields ranged from 31.0 to 68.2%. The substituents on aromatic ring influenced the yields of the product. It was found that, electron-donating group helped in increasing the nucleophilicity of the amino group of aryl hydrazides. Therefore, 4d (when substituent on aromatic ring was methoxyl group) obtained a yield of up to 68.2%. Solvent selection was critical in the last step. Ethyl alcohol was found to be the best solvent for refluxing. This is because, after cooling to room temperature the pure products 4a-4e formed easily, and required no further purification. When other solvents (such as acetonitrile) were used, both yield and purity were negatively affected.
The structures of compounds were elucidated by MS, 1H NMR and 13C NMR (All the copies of 1H NMR, 13C NMR and MS for all compounds are available in Supplementary Materials). All spectral data were in accordance with the assumed structures and are summarized in Table 1. In 1H NMR spectra, the three N-H protons of acylthiosemicarbazides 4a–4e were observed at 10.82–11.36, 10.49–10.57 and 10.15–10.31 ppm. Their 13C NMR spectra showed the characteristic carbon signals at δ 183.0 and δ 165.0, nearby attributed to C=S and C=O. The ESI-MS indicated that the molecular weights were in accordance to the calculated value.

2.2. Biological Study

2.2.1. Antibacterial Activity

Evaluation of antibacterial activity against a group of pathogenic microorganisms, including Gram-positive bacteria (Staphylococcus aureus), Gram-negative bacteria (Shigella Castellani, Escherichia coli and Pseudomonas aeruginosa), and fungi (Candida albicans), was carried out for the newly synthesized compounds. The results of the study are shown in Table 2. Antimicrobial activities are presented as the minimum inhibitory concentrations (MICs), which is the lowest concentration of the examined compound that resulted in more than 80% growth inhibition of the microorganism. In case of Gram-positive bacteria, 4a and 4c showed significant activity against Staphylococcus aureus with MIC at 10 μM. Except 4d, all compounds exhibited promising activity against Pseudomonas aeruginosa. In addition, 4c and 4e exhibited some antifungal activity with MICs of 10 and 20 μM, respectively. In general, 4c exhibited more potent antimicrobial activities compared to other compounds. Therefore, we infer that among the compounds studied, 4c can be taken as the lead compound for the development of novel antimicrobial agent.

2.2.2. Anti-Proliferative Activity Screening

All the synthesized compounds were evaluated for their cytotoxicity effect in five human cancer cell lines. The cell lines include; leukemia cell HL-60, acute lymphoblastic leukemia cell MT-4, cervical cancer cell Hela, hepatocellular carcinoma cell HepG2 and breast cancer cell MCF-The obtained IC50 of the synthesized compounds compared to the reference drug are shown in Table 3. The anti-proliferative activity results indicate that some of the target compounds possess notable anti-cancer properties. Interestingly, the highest activity in MT-4 is displayed by compounds 4a, 4b, 4d and 4e (IC50 = 18.42 ± 1.18, 15.73 ± 0.90, 10.96 ± 0.62 and 11.63 ± 0.11 μM), respectively. Compound 4d exhibited relatively high activity in HepG2 (IC50 = 29.05 ± 1.87 μM) cells compared to the Compound 4a (IC50 = 32.96 ± 0.81 μM). All compounds were proved inactive in HL-60 and MCF-7 cell lines.

2.2.3. Evaluation of Topo I Inhibitory Activity and Molecular Docking Study

DNA-topo I is an important enzyme in all living organisms, and it participates in many cellular metabolic processes, such as replication, transcription, recombination, and repair [19]. DNA topoisomerases have been established as molecular targets of anticancer drugs. The topo I inhibitory activity assay was carried out using the supercoiled DNA unwinding method [20]. A quantitative assay was carried out to assess the relative topo I inhibitory potency of the compounds and compared with the known topo I inhibitor camptothecin (CPT). The topo I inhibitory activity of the compounds is depicted in Figure 2. Similar to CPT, compounds 4b, 4d and 4e showed topo I inhibitory activity at 0.2 mM concentration. Compound 4a showed significant topo I inhibitory activity only at 1 mM. In many cases, the topo I inhibitory activity did not correlate well with the cytotoxicity. Compound 4d showed potent cytotoxicity in most of the cell lines but moderate topo 1 inhibitory activity, which may be related to other anticancer mechanisms.
To investigate the binding mode of potent inhibitor with human DNA-Topo I complex, molecular docking study was carried out by using Surflex-Dock in Sybyl-X 2.0. The 1T8I (PDB code) structure in Protein Data Bank was improved and used in the study. To validate the molecular docking approach used in this study, the crystallographic pose of CTP, derived from the DNA-Topo I complex structure (PDB ID 1T8I), and the top-ranked docking pose obtained in this study, were compared. The results indicated in Figure 3, depict the superposition of the two binding poses of CTP, inside the DNA-Topo I binding site. This superposition results in a RMSD (root-mean-square deviation) of superposition of 0.54 Å. The obtained RMSD value is far below the well-established tolerance level of 2.0 Å, thus validating the adopted docking methodology [21,22].
After running Surflex-Dock, the binding affinities of protein-ligand complexes were obtained and expressed as total score. The number of H-bonds and binding residues are indicated in Table 4. Docking results indicate that compounds (4a–4e) occupy the same binding site as that of CPT (Figure 4). The benz[c]acridine ring could take effect with the same base pair TGP11, DA113 and DC112, by π-π stacking force. Besides, the nitrogen and sulphur atoms in thiocarbamide moiety of compounds 4d and 4e, were found to have two hydrogen bonding interactions with the adenosine GLU356 and LYSAll these interactions helped them to anchor in the binding site of the protein and have good docking score as CPT, with total scores of 9.62, 10.31 and 10.27, respectively. Only one hydrogen bonding was formed in 4a–4c. As predicted, 4d and 4e exhibited remarkable topo I inhibitory activities.

2.2.4. Apoptosis and Cell-Cycle Analysis

The initiation of apoptosis and stages of cell cycle play an important role in progression of cancer. These two factors are considered crucial in cancer therapy [23,24]. The most active compound, 4d, was selected to study its effect on apoptosis and cell-cycle profile. As MT-4 cells were most sensitive to the activity of tested compounds, they were selected for testing Compound 4d for its effect on apoptosis and cell-cycle profile.
Determination of apoptosis was carried out using two methods viz. nuclear morphology determination (by use of dyes) and flow cytometry analysis (by determining apoptosis ratios). Nuclear morphological changes indicating tumor cell apoptosis were detected by using acridine orange (AO)/ethidium bromide (EB) stains. The use of these dyes facilitated a clear distinction between normal cells, early and late apoptotic cells, and necrotic cells [25]. No significant apoptosis was detected in the negative control group (Figure 5A). As evident in Figure 5B,C, the nuclei of MT-4 cells were markedly stained as yellow green or orange and the morphology displayed pycnosis, membrane blebbing and cell budding when treated with Compound 4d for 24 h. These findings indicate that Compound 4d could induce MT-4 cells apoptosis. With increasing concentrations, the number of apoptotic cells increased.
For determination of apoptosis ratios of Compound 4d in early and late stage apoptosis, flow cytometry analysis was used. MT-4 cells were treated with 6.25, 12.5 and 25 μM concentrations of 4d, and the apoptosis ratios were obtained. The four quadrant images describing, damaged, necrotic/apoptotic, normal and early apoptotic cells were observed in quadrants Q1, Q2, Q3, and Q4, respectively during flow cytometry analysis [26]. The sum of quadrants Q2 and Q4 is used to calculate the apoptosis ratio. As seen in Figure 6, the apoptosis ratios of Compound 4d measured at different concentration points were found to be 34.00% (6.25 μM), 44.73% (12.5 μM) and 57.72% (25 μM), respectively. The apoptosis ratio for control was found to be 9.96%. The obtained results thus indicate that Compound 4d suppressed cell proliferation by inducing apoptosis, and the apoptosis of MT-4 cells treated with Compound 4d increased gradually in a concentration-dependent manner.
The results of cell-cycle analysis performed in MT-4 cells, are represented in Figure 7. The results indicate that, Compound 4d exhibited 69.74%, 76.45%, and 85.15% of cell accumulation in G1 phase at 6.25 µM, 12.50 µM and 25.00 µM concentrations, respectively. However, in control (untreated cells) only 56.36% of cell accumulation in G1 phase was observed. These results indicate that Compound 4d induced a significant cell-cycle arrest in G1 phase in a concentration-dependent manner, compared to the control cells.

3. Materials and Methods

All chemicals were reagent grade and were purchased from commercial sources. All yields refer to isolated products after purification. NMR spectra were measured on a Bruker DRX-500 (1H: 400 MHz, 13C: 100 MHz) (Rheinstetten, Germany) using CDCl3 and DMSO-d6 as solvents. Chemical shifts (d) are expressed in parts per million (ppm), and J values are given in hertz (Hz). The mass spectra were obtained on a Thermo Fisher LCQ Fleet (ESI) instrument (Waltham, MA, USA). Melting points were determined using an Micro Melting-point Apparatus X-4A (Precision Instrument Co., Ltd., Shanghai, China) and were uncorrected.

3.1. Synthesis Methods

3.1.1. Synthesis of N-naphthyl-o-aminobenzoic Acid (1)

A mixture of 10.5 g bromobenzoic acid (26 mmoL), 9.8 g naphthylamine (68 mmoL), 15 g potassium carbonate (36.2 mmoL) and 0.6 g copper powder (9.4 mmoL) in isopentanol (60 mL) was stirred under reflux at 140 °C for 2 h. After the reaction, the isopentanol was removed under vacuum and the residue was diluted with 1200 mL water and then was stirred at 80 °C for 20 min. It was immediately filtered while hot. The water phase was acidified by hydrochloric acid upto pH 2, to facilitate precipitation. The precipitate was then filtered and recrystallized using chloroform to obtain greenish yellow solid, yield 79.0%, m.p. 204.8–208.4 °C.

3.1.2. Synthesis of 7-chlorine benz[c]acridine (2)

In a 250 mL round-bottom flask, Compound 1 3.36 g (13.8 mmoL) and phosphoryl chloride (9.18 mL) were added. The reaction mixture was stirred and heated to about 85–90 °C for 15 min. If liquid flooding occurred, the mixture was immediately removed from the hot bath until flooding ceased. The mixture was stirred for 2.5 h at 135–140 °C. On completion of the reaction, the solvent was removed from under pressure and the residue was poured into a mixture of 13.5 mL aqua ammoniac, 34.0 g crushed ice and 15 mL chloroform. Then, the water phase was extracted three times with 20 mL chloroform. The chloroform phase was dried with anhydrous calcium chloride overnight, filtered, evaporated and recrystallized with acetone to obtain faint yellow needle crystals, yield 67.5%, m.p. 140.1–141.7 °C.

3.1.3. Synthesis of 7-benz[c]acridine Isothiocyanate (3)

7-chlorine benz[c]acridine (1.84 g, 7 mmol) was dissolved in acetone (60 mL), followed by addition of NaSCN (1.14 g, 14 mmol) and tetrabutylammonium bromide (0.21 g, 0.7 mmol). After 1.5 h refluxing with stirring, the reaction mixture was cooled to room temperature. The formed bright yellow needle crystals were fifiltered, washed with water, and dried under vacuum. Yield 82.0%, m.p. 230–233 °C. ESI-MS: m/z: 287 [(M + H)+]; 1H-NMR (CDCl3, 600 MHz): δ 9.47 (d, J = 7.8 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 8.32–8.22 (m, 1H), 8.01 (d, J = 9.2 Hz, 1H), 7.89 (dd, J = 8.4, 5.9 Hz, 2H), 7.83–7.75 (m, 3H), 7.71 (ddd, J = 8.1, 6.7, 1.2 Hz, 1H); 13C-NMR (CDCl3, 150 MHz): δ 147.96, 147.61, 140.26, 133.61, 131.12, 130.32, 129.61, 129.32, 128.13, 127.89, 127.15, 125.45, 122.68, 120.39, 120.11.

3.1.4. General Procedure for the Synthesis of 1-Aryl-4-(7-benz[c]acridinyl) Thiosemicarbazides Derivatives 4a–e

To a solution of 7-benz[c]acridine isothiocyanate 3 (0.2 g, 0.7 mmol) in absolute ethyl alcohol (50 mL), the appropriate substituted hydrazides (0.8 mmol) were added and the reaction mixture was refluxed until the reactants were consumed. The formed precipitate was filtered off, washed with a small amount of hot ethyl alcohol and dried at room temperature to give pure products 4a–e.
  • 1-Pyridyl-4-(7-benz[c]acridinyl) Thiosemicarbazides (4a): Orange-yellow powder, yield 46.7%, m.p. 177.4–180.9 °C.
  • 1-(4-chlorin-phenyl)-4-(7-benz[c]acridinyl) Thiosemicarbazides (4b): Orange-yellow powder, yield 34.0%, m.p. 203.3–203.9 °C.
  • 1-(4-nitro-phenyl)-4-(7-benz[c]acridinyl) Thiosemicarbazides (4c): Orange-red powder, yield 31.0%, m.p. 238.7–240.1 °C.
  • 1-(4-methoxy-phenyl)-4-(7-benz[c]acridinyl) Thiosemicarbazides (4d): Orange-yellow powder, yield 68.2%, m.p. 184.2–187.4 °C.
  • 1-phenyl-4-(7-benz[c]acridinyl) Thiosemicarbazides (4e): Orange-yellow powder, yield 58.6%, m.p. 181.4–182.9 °C

3.2. Biological Activity

3.2.1. Antimicrobial Activity

The in vitro anti-bacterial activity testing of the thiosemicarbazides derivatives (4a–4e) was carried out by tube dilution method [27] using Gram-positive (Staphylococcus aureus) and Gram-negative bacteria (Shigella Castellani, and Escherichia coli). The antifungal effect was screened against Candida albicans. Dimethyl sulfoxide was used as a solvent to prepare the stock solutions of the test and reference compound (streptomycin). For bacteria and fungi, double strength nutrient broth I.P. and sabouraud dextrose broth I.P., respectively were used for preparing serial dilutions of the test and reference compound. [28]. The incubation period used for inoculated plates of bacteria and fungi were 24 h and 48 h, respectively at 37 °C. The results were recorded in terms of the minimum inhibitory concentration (MIC). The MIC was defined as the lowest concentration of the tested compound inhibiting the visible growth of each microorganism. Each test was carried out in triplicate.

3.2.2. Antiproliferative Activity

MTS Assay

Cytotoxicity in cells was investigated by MTS method [29]. A panel of five human cancer cell lines including leukemia cell HL-60, acute lymphoblastic leukemia cell MT-4, cervical cancer cell Hela, hepatocellular carcinoma cell HepG2 and breast cancer cell MCF-7, were used. All these tumor cell lines were obtained from Kunming Institute of Botany. Briefly, cells were seeded on 96-well plates at a density of 4 × 103–15 × 103 cells/well, incubated for 24 h at 37 °C. These were then treated with test drugs and cisplatin for 48 h. To determine the live cell numbers, MTS (3-(4,5-dimethylthiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, Madison, WI, USA) was added to the cells and allowed to develop for 2–4 h. Colorimetric measurements were taken at 492 nm. The drug concentrations resulting in 50% inhibition of cell growth (IC50) were determined by Reed and Muench method.

3.3. Topo I Inhibitory Activity

Supercoiled pBR32 DNA was used a substrate to determine the Topo I catalytic activity [29]. Commercial samples of Topo I and pBR322 were obtained from Takara Biotechnology (Dalian) Co.,Ltd.Takara Bio Inc. (Dalian, China). The buffer solutions were prepared using 500 mM KAc, 200 mM Tris-Ac, 100 mM Mg(Ac)2 and 1 mg/mL BSA. The procedure used for determination of enzyme inhibitory activity was similar to one reported by Xu et al. [30].

3.4. Molecular Docking

The Surflex-Dock in Sybyl-X version 2.0 by Tripos Associates (L.P. St. Louis, MO, USA) was used for molecular docking. This system performs molecular docking functions aided by the generation of an idealized active site (Protocol), consisting of dummy atoms that guide the docking process. The crystal structures of DNA-Topo I complex was downloaded from the Research Collaboration for Structural Bioinformatics (RCSB) website (www.rcsb.com) (PDB ID: 1T8I). The proteins were then imported into the Surflex-Dock, and prepared for docking using the biopolymer preparation tool according to the following criteria: H-Addition, H-Bond, removal of water molecules, termini treatment, charge, protonation, type of histidines.
The structures of the compounds were sketched using software of ChemBioOffice version 14.0 by PerkinElmer (Waltham, MA, USA). The alignments of the training set molecules were derived by using FlexS in Sybyl–X. All values were filled with valence, and Gasteiger–Marsili charges were calculated for each compound. Ultimately, ligand docking under the Surflex–Dock GeomX precision was performed to generate grid of protein and ligands. The docking results were then imported into the LigPlot+ 2.1, and the combination of compounds and proteins were discussed by H-Bond, conjugate action, and hydrophilic or hydrophobic action.

3.5. General Procedure for AO/EB Staining

Apoptosis was determined by nuclear morphology. Cells were fixed and stained with AO/EB according to the manufacturer’s instruction (KGA501, KeyGEN BioTECH, Nanjing, China). MT-4 cells were seeded in 6-well plates with a sterile cover slip. The concentration of cells used per well was 5 × 105–6 × 106 cells/2 mL. To facilitate growth, the medium was replaced with fresh medium (RPMI1640) plus 10% fetal bovine serum. The fresh medium was supplemented with Compound 4d (12.50 μM and 25 μM). Post-treatment, 25 μL of cell suspension was collected on a glass slide by inverting the cover slip and stained with 10 μL of AO/EB stain (100 mg/mL). Finally, stained nuclei were observed immediately under a fluorescence microscope (BX41, Nikon, Tokyo, Japan).

3.6. General Procedure for Apoptosis Ratio Determination

For determination of apoptosis ratios by application of flow cytometry analysis, the manufacturer’s protocol (KGA1024, KeyGEN BioTECH, Nanjing, China) for Annexin-V APC/7-AAD double-stain assay was used. Briefly, the prepared MT-4 cells (5 × 105 cells/mL) were collected and resuspended in 500 μL of binding buffer containing 5 μL of Annexin V-APC. The suspension was shaken well and 5μL of 7-AAD was added to it. The suspension was then incubated for 5–15 min in the dark at room temperature. Post-incubation, the suspension was immediately analyzed using a flow cytometer (FACS Cali-bur, Becton Dickinson, Mountain View, CA, USA).

3.7. General Procedure Cell Cycle

MT-4 cell cultures were treated with the indicated concentrations of Compound 4d for 48 h incubation. The cells were washed twice with ice-cold phosphate buffer saline (PBS), fixed and permeabilized with ice-cold 70% ethanol at 4 °C for 2 h. The cells were treated with 100 μL RNase A at 37 °C for 30 min after washing with ice-cold PBS. Then they were stained with 400 μL 1 PI (1 mg/mL), in the dark at 4 °C for 30 min. Cell-cycle analysis was performed by flow cytometry (FACS Verse, BD, USA), at an excitation wavelength of 488 nm.

4. Conclusions

The study provides a systematic synthesis scheme for acridine thiosemicarbazides derivatives with possible anti-cancer and anti-microbial activity. Through application of spectral evaluation and in vitro studies, the potential anti-tumor activity of Compound 4d and anti-microbial activity of Compound 4c is demonstrated. In the study of pharmacological mechanism, most of the compounds except 4b exhibited potent topo I inhibitory activity at 0.2 mM. The apoptosis-inducing activity of the representative Compound 4d in MT-4 cells was studied, and the results revealed that this compound showed clear cell apoptosis-inducing effects. Cell-cycle analysis indicated that Compound 4d could arrest MT-4 cells in G1 stage. The study demonstrates that the rational design of naphtho-fused acridine thiosemicarbazide derivatives as novel antitumor or anti-microbial leads compared to existing anti-cancer agents is feasible.

Supplementary Materials

All the copies of 1H NMR, 13C NMR and MS for the title compounds are available online.

Author Contributions

L.H., J.H. and Z.Y. contributed to the synthesis of compounds. R.C., J.Z., X.X., Z.Z., and Y.L. performed pharmacological activity testing and docking study of the target products. L.H. and R.C. wrote the manuscript. Y.J. and L.W. contributed to improvising the manuscript, providing intellectual inputs and editing the language of the manuscript.

Funding

This research received no external funding.

Acknowledgments

This work acknowledges the support of the National Natural Science Foundation of China (No. NSFC81603525); Guangxi Natural Science Foundation (No.2017GXNSFAA198171 and No.2018GXNSFBA138008); State Key Laboratory Cultivation Base for the Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Science and Technology of China (CMEMR2015-B04 and CMEMR2015-B05); Talent Cultivation Construction Project of Professor Yang Shilin’s Team (No.YSL17003); Promotion project of basic ability of young and middle-aged teachers in colleges and universities in Guangxi (No.2017KY0283); Hundred Talents Plan for the Introduction of High-Level Overseas Talents by Guangxi Colleges and Universities; Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine [(2013) No. 20], Collaborative Innovation Center of Zhuang and Yao Ethnic Medicine ((2014) No. 32), Guangxi Key Discipline Zhuang Pharmacology [(2013) No. 16], Guangxi T.C.M. Innovation Theory and Efficacy Research Team (BaGui Scholar) (J13162).

Conflicts of Interest

The authors declare no conflicts of interest in association with this manuscript.

References

  1. Lang, X.; Luan, X.; Gao, C.; Jiang, Y. Recent Progress of Acridine Derivatives with Antitumor Activity. Prog. Chem. 2012, 24, 1497–1505. [Google Scholar]
  2. Wang, S.S.; Lee, Y.J.; Hsu, S.C.; Chang, H.O.; Yin, W.K.; Chang, L.S.; Chou, S.Y. Linker-modified triamine-linked acridine dimers: Synthesis and cytotoxicity properties in vitro and in vivo. Bioorganic Med. Chem. 2007, 15, 735–748. [Google Scholar] [CrossRef] [PubMed]
  3. Sánchez, I.; Reches, R.; Caignard, D.H.; Renard, P.; Pujol, M.D. Synthesis andbiological evaluation ofmodified acridines: The effect of N- and O- substituent inthenitrogenated ring onantitumor activity. Cheminform 2006, 41, 340–352. [Google Scholar]
  4. Bacherikov, V.A.; Chang, J.Y.; Lin, Y.W.; Chen, C.H.; Pan, W.Y.; Dong, H.; Lee, R.Z.; Chou, T.C.; Su, T.L. Synthesis and antitumor activity of 5-(9-acridinylamino) anisidine derivatives. Bioorganic Med. Chem. 2005, 23, 6513–6520. [Google Scholar] [CrossRef]
  5. Vispé, S.; Vandenberghe, I.; Robin, M.; Annereau, J.P.; Créancier, L.; Pique, V.; Galy, J.P.; Kruczynski, A.; Barret, J.M.; Bailly, C. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem. Pharmacol. 2007, 73, 1863–1872. [Google Scholar] [CrossRef] [PubMed]
  6. Belmont, P.; Bosson, J.; Godet, T.; Tiano, M. Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now? Anti-Cancer Agents Med. Chem. 2007, 2, 139–169. [Google Scholar] [CrossRef]
  7. Oppegard, L.M.; Ougolkov, A.V.; Luchini, D.N.; Schoon, R.A.; Goodell, J.R.; Kaur, H.; Billadeau, D.D.; Ferguson, D.M.; Hiasaa, H. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur. J. Pharmacol. 2009, 602, 223–229. [Google Scholar] [CrossRef] [Green Version]
  8. Cain, B.F.; Atwell, G.J.; Denny, W.A. Potential antitumor agents 17. 9-Anilino-10-Methylacridinium Salts. J. Med. Chem. 1976, 19, 772–777. [Google Scholar] [CrossRef]
  9. Kimura, M.; Okabayashi, I.; Kato, A. Acridine derivatives. III. Preparation and antitumor activity of the novel acridinyl-substituted uracils. Chem. Pharm. Bull. 1989, 37, 697. [Google Scholar] [CrossRef]
  10. Gamage, S.A.; Spicer, J.A.; Rewcastle, G.W.; Denny, W.A. A new synthesis of substituted acridine-4-carboxylic acids and the anticancer drug N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Tetrahedron Lett. 1997, 38, 699–702. [Google Scholar] [CrossRef]
  11. Abbas, S.Y.; Elsharief, M.A.; Basyouni, W.M.; Fakhr, I.M.; Elgammal, E.W. Thiourea derivatives incorporating a hippuric acid moiety: Synthesis and evaluation of antibacterial and antifungal activities. Eur. J. Med. Chem. 2013, 64, 111–120. [Google Scholar] [CrossRef] [PubMed]
  12. Saeed, S.; Rashid, N.; Jones, P.G.; Ali, M.; Hussain, R. Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents. Eur. J. Med. Chem. 2010, 45, 1323–1331. [Google Scholar] [CrossRef]
  13. Zhong, Z.; Xing, R.; Liu, S.; Wang, L.; Cai, S.; Li, P. Synthesis of acyl thiourea derivatives of chitosan and their antimicrobial activities in vitro. Carbohydr. Res. 2008, 343, 566–570. [Google Scholar] [CrossRef] [PubMed]
  14. Rao, X.P.; Wu, Y.; Song, Z.Q.; Shang, S.B.; Wang, Z.D. Synthesis and antitumor activities of unsymmetrically disubstituted acylthioureas fused with hydrophenanthrene structure. Med. Chem. Res. 2011, 20, 333–338. [Google Scholar] [CrossRef]
  15. Burgeson, J.R.; Moore, A.L.; Boutilier, J.K.; Cerruti, N.R.; Gharaibeh, D.N.; Lovejoy, C.E.; Amberg, S.M.; Hruby, D.E.; Tyavanagimatt, S.R.; AllenIII, R.D. SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity. Bioorganic Med. Chem. Lett. 2012, 22, 4263–4272. [Google Scholar] [CrossRef] [PubMed]
  16. Limban, C.; Vasile, A.; Chirita, I.C.; Caproiu, M. Preparation of new thiourea derivatives with potential anti-parasitic and antimicrobial activity. Rev. De Chim. 2010, 61, 946–950. [Google Scholar]
  17. Burgess, S.J.; Audrey, S.; Jane Xu, K.; Smilkstein, M.J.; Riscoe, M.K.; Peyton, D.H. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J. Med. Chem. 2006, 49, 5623. [Google Scholar] [CrossRef]
  18. Solinas, A.; Faure, H.; Roudaut, H.; Traiffort, E.; Schoenfelder, A.; Mann, A.; Manetti, F.; Taddei, M.; Ruat, M. Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity. J. Med. Chem. 2012, 55, 1559–1571. [Google Scholar] [CrossRef]
  19. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998, 80, 255–270. [Google Scholar] [CrossRef]
  20. Zhao, L.X.; Moon, Y.S.; Basnet, A.; Kim, E.K.; Jahng, Y.; Park, J.G.; Jeong, T.C.; Cho, W.J.; Choi, S.U.; Chong, O.L. Synthesis, topoisomerase I inhibition and structure–activity relationship study of 2,4,6-trisubstituted pyridine derivatives. Bioorganic Med. Chem. Lett. 2004, 14, 1333–1337. [Google Scholar] [CrossRef]
  21. Lill, M. Virtual screening in drug design. Silico Models Drug Discov. 2013, 993, 1–12. [Google Scholar]
  22. Hevener, K.E.; Zhao, W.; Ball, D.M.; Babaoglu, K.; Qi, J.; White, S.W.; Lee, R.E. Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. J. Chem. Inf. Modeling 2009, 2, 444–460. [Google Scholar] [CrossRef]
  23. Maddika, S.; RaoAnde, S.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K.D.; Wiechec, E.; Los, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updates 2007, 10, 13–29. [Google Scholar] [CrossRef] [Green Version]
  24. Bunz, F. Cell death and cancer therapy. Curr. Opin. Pharmacol. 2001, 1, 337–341. [Google Scholar] [CrossRef]
  25. Liu, K.; Liu, P.; Liu, R.; Wu, X. Dual AO/EB staining to detect apoptosis in osteosarcoma cells compared with flow cytometry. Med. Sci. Monit. Basic Res. 2015, 21, 15–20. [Google Scholar] [PubMed]
  26. Huang, X.C.; Wang, M.; Wang, H.S.; Chen, Z.F.; Zhang, Y.; Pan, Y.M. Synthesis and antitumor activities of novel dipeptide derivatives derived from dehydroabietic acid. Bioorganic Med. Chem. Lett. 2014, 24, 1511–1518. [Google Scholar] [CrossRef]
  27. Cappuccino, J.; Sherman, N. Microbiology: A Laboratory Manual, 4th ed.; Addison Wesley Longman Inc.: Reading, MA, USA, 1999; p. 263. [Google Scholar]
  28. Ministry of Health & Family welfare, Government of india. Indian Pharmacopoeia 2007, 5th ed.; The Indian Pharmacopoeia Commission: Ghaziabad, India, 2007; Volume 1, p. 37.
  29. Jin, Y.; Chen, Q.; Shi, X.; Lu, Z.; Cheng, C.; Lai, Y.; Zheng, Q.; Pan, J. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci. 2009, 100, 1335–1343. [Google Scholar] [CrossRef]
  30. Xu, Y.; Jing, D.; Chen, R.; Haroon, U.R.; Jiang, J.; Liu, X.; Wang, L.; Wang, P. Design, synthesis and evaluation of novel sophoridinic imine derivatives containing conjugated planar structure as potent anticancer agents. Bioorgnic Med. Chem. 2018, 26, 4136–4144. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds 4a–4e are available from the authors.
Molecules 24 02065 g001 550
Figure 1. Hybrids of acridine and thiourea group giving acridine thiosemicarbazides.
Figure 1. Hybrids of acridine and thiourea group giving acridine thiosemicarbazides.
Molecules 24 02065 g001
Molecules 24 02065 sch001 550
Scheme 1. The synthesis of acridinyl aroyl thiourea derivatives (4a–4e).
Scheme 1. The synthesis of acridinyl aroyl thiourea derivatives (4a–4e).
Molecules 24 02065 sch001
Molecules 24 02065 g002 550
Figure 2. DNA-topo I inhibitory activity of 4a–4e using camptothecin (CPT) (0.2 mM) as a positive control.
Figure 2. DNA-topo I inhibitory activity of 4a–4e using camptothecin (CPT) (0.2 mM) as a positive control.
Molecules 24 02065 g002
Molecules 24 02065 g003 550
Figure 3. Result of validation for Topo I inhibitor camptothecin (CPT), inside the enzyme active site (derived from PDB ID 1T8I).
Figure 3. Result of validation for Topo I inhibitor camptothecin (CPT), inside the enzyme active site (derived from PDB ID 1T8I).
Molecules 24 02065 g003
Molecules 24 02065 g004 550
Figure 4. The best pose of the binding mode of compounds with DNA-Topo I complex (PDB:1T8I). (A: CPT, B: 4a, C: 4b, D: 4c, E: 4d F: 4e).
Figure 4. The best pose of the binding mode of compounds with DNA-Topo I complex (PDB:1T8I). (A: CPT, B: 4a, C: 4b, D: 4c, E: 4d F: 4e).
Molecules 24 02065 g004
Molecules 24 02065 g005 550
Figure 5. AO/EB staining of Compound 4d in MT-4 cells. (A) Cells not treated with 4d (control) and (B) cells treated with Compound 4d at 12.50 μM and, (C) cells treated with Compound 4d at 25 μM concentration.
Figure 5. AO/EB staining of Compound 4d in MT-4 cells. (A) Cells not treated with 4d (control) and (B) cells treated with Compound 4d at 12.50 μM and, (C) cells treated with Compound 4d at 25 μM concentration.
Molecules 24 02065 g005
Molecules 24 02065 g006 550
Figure 6. Apoptosis ratio detection of Compound 4d by Annexin V/PI assay. (A) Not treated with Compound 4d (control) for 48 h and, (B) treatment with Compound 4d at 6.25 μM, (C) treatment with Compound 4d at 12.50 μM and (D) treatment with Compound 4d at 25 μM for 48 h each, respectively, (E) The percentage of quadrants Q2 and Q4 was shown as mean ± SD. Data is the representative of three independent experiments. * p < 0.05, ** p < 0.01.
Figure 6. Apoptosis ratio detection of Compound 4d by Annexin V/PI assay. (A) Not treated with Compound 4d (control) for 48 h and, (B) treatment with Compound 4d at 6.25 μM, (C) treatment with Compound 4d at 12.50 μM and (D) treatment with Compound 4d at 25 μM for 48 h each, respectively, (E) The percentage of quadrants Q2 and Q4 was shown as mean ± SD. Data is the representative of three independent experiments. * p < 0.05, ** p < 0.01.
Molecules 24 02065 g006
Molecules 24 02065 g007 550
Figure 7. Cell-cycle analysis of MT-4 cells treated with Compound 4d, by flow cytometry. (A) Not treated with Compound 4d (control) for 48 h (B) treatment with Compound 4d at 6.25 μM, (C) treatment with Compound 4d at 12.50 μM and, (D) treatment with Compound 4d at 25 μM for 48 h each, respectively, (E) The percentage of each population was shown as mean ± SD. Data is the representative of three independent experiments. * p < 0.05, ** p < 0.01.
Figure 7. Cell-cycle analysis of MT-4 cells treated with Compound 4d, by flow cytometry. (A) Not treated with Compound 4d (control) for 48 h (B) treatment with Compound 4d at 6.25 μM, (C) treatment with Compound 4d at 12.50 μM and, (D) treatment with Compound 4d at 25 μM for 48 h each, respectively, (E) The percentage of each population was shown as mean ± SD. Data is the representative of three independent experiments. * p < 0.05, ** p < 0.01.
Molecules 24 02065 g007
Table
Table 1. The spectral data of the compounds (4a–4e).
Table 1. The spectral data of the compounds (4a–4e).
Comp.ArYield (%)1H NMR (DMSO-d6) δ ppm (J in Hz)13C NMR (DMSO-d6)ESI-MS: m/z: [(M − H)]−Melting Point (°C)
4a Molecules 24 02065 i00246.7%11.36 (s, 1H, -NH), 10.55 (s, 1H, -NH), 10.31 (s, 1H, -NH), 9.38~9.41 (m, 1H, ArH), 8.81 (d, 2H, J = 4.4Hz, ArH), 8.33 (d, 1H, J = 8.8Hz, ArH), 8.21 (d, 1H, J = 8.4Hz, ArH), 8.04 (t, 1H, ArH), 7.90~7.97 (m, 5H, ArH), 7.82~7.84 (m, 2H, ArH), 7.73 (t, 1H, ArH)183.36, 165.46, 150.71, 147.98, 147.88, 142.04, 139.99, 133.88, 131.24, 130.68, 129.99, 129.83, 128.65, 128.09, 128.01, 126.80, 125.34, 125.11, 124.94, 123.22, 122.51, 122.32.422177.4–180.9 °C
4b Molecules 24 02065 i00334.0%11.09 (s, 1H, -NH), 10.52 (s, 1H, -NH), 10.23 (s, 1H, -NH), 9.40 (t, 1H, ArH), 8.33 (d, 1H, J = 8.4Hz, ArH), 8.22 (d, 1H, J = 8.8Hz, ArH), 8.03~8.09 (m, 3H, ArH), 7.90~7.97 (m,3H, ArH), 7.82~7.84 (m, 2H, ArH), 7.73 (t, 1H, ArH), 7.64 (d, 2H, J = 8.4, ArH)183.49, 165.96, 147.98, 147.87, 142.22, 137.27, 133.89, 131.78, 131.26, 130.62, 130.47,129.95, 129.79, 128.85, 128.62, 127.96, 126.71, 125.39, 125.11, 125.02, 123.25, 122.61.455203.3–203.9 °C
4c Molecules 24 02065 i00431.0%11.32 (s, 1H, -NH), 10.57 (s, 1H, -NH), 10.32 (s, 1H, -NH), 9.40 (t, 1H, ArH), 8.40 (d, 2H, J = 8.0Hz, ArH), 8.34 (d, 1H, J = 8.8Hz, ArH), 8.28 (d, 2H, J = 8.4Hz, ArH), 8.21 (d, 1H, J = 8.4Hz, ArH), 8.05 (t, 1H, ArH), 7.91~7.97 (m, 3H, ArH), 7.82~7.84 (m, 2H, ArH), 7.74 (t, 1H, ArH)183.29, 165.42, 149.88, 147.99, 147.88, 142.09, 138.76, 133.89, 131.25, 130.68, 130.05, 129.98, 129.84, 128.65, 128.09, 128.00, 126.80, 125.37, 125.12, 124.95, 123.93, 123.24, 122.52,466238.7–240.1 °C
4d Molecules 24 02065 i00568.2%10.82 (s, 1H, -NH), 10.49 (s, 1H, -NH), 10.15 (s, 1H, -NH), 9.40 (t, 1H, ArH), 8.33 (d, 1H, J = 8.8Hz, ArH), 8.23 (d, 1H, J = 8.4Hz, ArH), 7.90~8.05 (m, 6H, ArH), 7.90~7.93 (m, 2H, ArH), 7.82~7.84 (m, 1H, ArH), 7.73 (t, 2H, ArH), 3.83 (s, 3H, OCH3).183.60, 166.39, 147.99, 142.22, 147.86, 142.41, 133.90, 131.27, 130.58, 130.47, 129.92, 128.77, 128.61, 127.93, 126.64, 126.63, 125.45, 125.11, 123.28, 122.72, 113.97, 55.92.451184.2–187.4 °C
4e Molecules 24 02065 i00658.6%11.09 (s, 1H, -NH), 10.52 (s, 1H, -NH), 10.19 (s, 1H, -NH), 9.40 (dd, J = 6.1, 3.5 Hz, 1H, ArH), 8.32 (d, J = 8.6 Hz, 1H, ArH), 8.25 (d, J = 8.5 Hz, 1H, ArH), 8.10 (d, J = 7.7 Hz, 2H, ArH), 8.04 (dd, J = 6.0, 3.2 Hz, 1H, ArH), 7.99 (d, J = 9.3 Hz, 1H, ArH), 7.95~7.88 (m, 2H, ArH), 7.83 (dt, J = 6.1, 3.6 Hz, 2H, ArH), 7.72 (t, J = 7.6 Hz, 1H, ArH), 7.60 (d, J = 7.2 Hz, 1H, ArH), 7.54 (t, J = 7.5 Hz, 2H, ArH).183.51, 166.82, 147.98, 147.86, 142.39, 133.90, 132.93, 131.26, 130.59, 129.92, 129.75, 128.71, 128.61, 127.93, 126.64, 125.43, 125.09, 123.26, 123.26, 122.74421181.4–182.9 °C
Table
Table 2. Antibacterial activity of 4a–4e presented as the minimum inhibitory concentration (MIC) (μM).
Table 2. Antibacterial activity of 4a–4e presented as the minimum inhibitory concentration (MIC) (μM).
CompoundsGram-Positive BacteriaGram-Negative BacteriaAntifungal Activity
Staphylococcus aureusShigella CastellaniEscherichia coliPseudomonas aeruginosaCandida albicans
4a10>100>10010>100
4b4020>1002080
4c1010201010
4d>100>100>100>10040
4e4080>1002020
Streptomycin22222
Table
Table 3. The IC50 value of the synthesized compounds obtained for anti-proliferative activity on different tumor cell lines (μM).
Table 3. The IC50 value of the synthesized compounds obtained for anti-proliferative activity on different tumor cell lines (μM).
CompoundsHL-60MT-4HelaHepG2MCF-7
4a>10018.42 ± 1.1830.93 ± 1.7832.96 ± 0.81>100
4b>10015.73 ± 0.9045.68 ± 2.1454.80 ± 2.95>100
4c>10057.59 ± 2.3759.39 ± 2.5651.60 ± 2.46>100
4d59.56 ± 2.5410.96 ± 0.6242.04 ± 2.0729.05 ± 1.87>100
4e70.19 ± 3.7211.63 ± 0.1168.18 ± 3.9258.99 ± 3.11>100
cisplatin3.66 ± 0.145.99 ± 0.126.65 ± 0.1214.45 ± 0.4925.92 ± 1.68
Table
Table 4. Interactions between DNA-Topo I (from PDB ID 1T8I) and the compounds.
Table 4. Interactions between DNA-Topo I (from PDB ID 1T8I) and the compounds.
CompoundAmino AcidTypeHydrophobic ResidueBinding Affinity (Total Score)
4aTGP11π-πDA113, ARG364, TGP11, DT10, DT9, DC1128.82
DA113 π-π
DC112π-π
ASN722Hydrogen Bond
4bTGP11π-πARG364, DC112, TGP11, DT107.82
DA113π-π
DT10π-π
DC112π-π
DA113Hydrogen Bond
4cTGP11π-πTGP11, THR718, DT10,DT9, DA113, DC1128.32
DA113π-π
DC112π-π
ARG364Hydrogen Bond
4dTGP11π-πARG364, DT10, DA113, ASN352, TRP416, LYS374, GLU418, DC112, TGP1110.31
DA113π-π
DC112π-π
LYS452Hydrogen Bond
GLU356Hydrogen Bond
4eTGP11π-πDT10, TGP11, ARG364, DC112, TRP416, GLU418, ASN352,DA1139.62
DA113π-π
DC112π-π
LYS425 Hydrogen Bond
GLU356Hydrogen Bond
CPTTGP11π-πDC112, DA113, TGP11, DT10, DG1210.27
DA113π-π
DC112π-π
ASP533Hydrogen Bond
ARP364Hydrogen Bond

Share and Cite

MDPI and ACS Style

Chen, R.; Huo, L.; Jaiswal, Y.; Huang, J.; Zhong, Z.; Zhong, J.; Williams, L.; Xia, X.; Liang, Y.; Yan, Z. Design, Synthesis, Antimicrobial, and Anticancer Activities of Acridine Thiosemicarbazides Derivatives. Molecules 2019, 24, 2065. https://doi.org/10.3390/molecules24112065

AMA Style

Chen R, Huo L, Jaiswal Y, Huang J, Zhong Z, Zhong J, Williams L, Xia X, Liang Y, Yan Z. Design, Synthesis, Antimicrobial, and Anticancer Activities of Acridine Thiosemicarbazides Derivatives. Molecules. 2019; 24(11):2065. https://doi.org/10.3390/molecules24112065

Chicago/Turabian Style

Chen, Rui, Lini Huo, Yogini Jaiswal, Jiayong Huang, Zhenguo Zhong, Jing Zhong, Leonard Williams, Xing Xia, Yan Liang, and Zhenshuo Yan. 2019. "Design, Synthesis, Antimicrobial, and Anticancer Activities of Acridine Thiosemicarbazides Derivatives" Molecules 24, no. 11: 2065. https://doi.org/10.3390/molecules24112065

Article Metrics

Back to TopTop